Testing is where Thailand's AI adoption often pays off quickly, because it reduces waiting. AI can draft unit tests from code, suggest regression ...

This important study analyzed the impact of amino acid homorepeats on protein expression and solubility in yeast and E. coli. The authors provided convincing evidence that hydrophobic and positively ...

MPC Paris delivered 575 shots on Cold Storage, from invisible fixes to slime, creatures and a nuclear finale. But how?

This study presents valuable findings implicating nuclear export in the regulation of protein condensate behaviour and TDP-43 phase behaviour, suggesting a link to pathogenic aggregation in ALS/FTD.

A closely watched clinical trial in Britain that screened blood for early detection of cancer did not show a reduction in diagnoses at later stages of the disease. By Rebecca Robbins and Gina Kolata A ...

“Bad,” or LDL, cholesterol is a major risk factor for heart disease and most people are screened for it as part of their yearly physicals. There’s another marker in the blood that may be a better ...

A dress rehearsal countdown for NASA's Artemis II moon rocket, intended to clear the way for a possible February launch, ran into a variety of problems and ultimately was called off early Tuesday ...

Meta plans to test new subscriptions that give people access to exclusive features on its apps, the company told TechCrunch on Monday. The tech giant said the new subscriptions will unlock more ...

Leaders often think of software engineering quality as something that slows down development. But when teams build software carefully from the start, they find they have fewer problems to fix later.

ProPublica is a nonprofit newsroom that investigates abuses of power. Sign up to receive our biggest stories as soon as they’re published. These highlights were written by the reporters and editors ...

Software testing is a crucial but time-consuming aspect of software development, and recently, Large Language Models (LLMs) have gained popularity for automated test case generation. However, because ...

Pfizer’s recent bidding war for an obesity biotech clearly hasn’t satiated the pharma’s appetite for new GLP-1 therapies—at least going by this morning’s $1.9 billion biobucks deal. The U.S. drugmaker ...